Results 221 to 230 of about 2,474,961 (353)

Correction: Gut microbiota affects PD-L1 therapy and its mechanism in melanoma. [PDF]

Cancer Immunol Immunother
Liu S, Liu J, Mei Y, Zhang W.
europepmc   +1 more source

2K1648 Mechanisms of ligand recognition by the amino acid chemoreceptors of Vibrio cholerae(Cell biology 2,The 48th Annual Meeting of the Biophysical Society of Japan)

, 2011
So‐ichiro Nishiyama, Kimiko Yamamoto, Hirotaka Tajima, Tetsuya Kawaguchi, Hideaki Sekiguchi, Ikuro Kawagishi   +5 more
openalex   +2 more sources

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

A multimodal transformer-based visual question answering method integrating local and global information. [PDF]

PLoS One
Huang C, Hu Z.
europepmc   +1 more source

Elucidating Mechanisms of Toxicity Using Phenotypic Data from Primary Human Cell Systems—A Chemical Biology Approach for Thrombosis-Related Side Effects [PDF]

, 2015
Ellen L. Berg, Mark A. Polokoff, Alison O’Mahony, Dat Nguyen, Xitong Li   +4 more
openalex   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

The neonatal Fc receptor (FcRn): Guardian or Trojan Horse in viral infection? [PDF]

PLoS Pathog
Na L, Zheng Y, Yang JB, Bao HL, Tang YD.
europepmc   +1 more source

1G1510 Mechanisms of signal transduction activated by heavy-ion microbeam induced bystander responses(Cell Biology I,Oral Presentation,The 50th Annual Meeting of the Biophysical Society of Japan)

, 2012
Masanori Tomita, Hideki Matsumoto, Tomoo Funayama, Yuichiro Yokota, Kensuke Otsuka, Munetoshi Maeda, Yasuhiko Kobayashi   +6 more
openalex   +2 more sources

Deciphering the pharmacological mechanism of the Chinese formula Huanglian-Jie-Du decoction in the treatment of ischemic stroke using a systems biology-based strategy [PDF]

, 2015
Yanqiong Zhang, Songsong Wang, Weiliang Zhu, Yan Ma, Fangbo Zhang, Rixin Liang, Haiyu Xu, Hongjun Yang   +7 more
openalex   +1 more source

RNAi: Mechanisms, biology and applications [PDF]

FEBS Letters, 2005
openaire   +2 more sources